Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Bliss GVS Pharma Ltd (BLISSGVS)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 506197 NSE: BLISSGVS Pharmaceuticals & Drugs | Small Cap | Bliss GVS Pharma Share Price
₹704 13.60 (1.97%)
As on 23-Sep'26 11:43
Bliss GVS Pharma Ltd (BLISSGVS)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 506197 NSE: BLISSGVS Pharmaceuticals & Drugs | Small Cap | Bliss GVS Pharma Share Price
₹704 13.60 (1.97%)
As on 23-Sep'26 11:43
Key Metrics
Valuation Multiples
Market Cap
₹7,341 Cr.
Current Price
₹704
52-Week Low / High
₹118 / 734
TTM EPS
₹12.8
TTM Sales
₹1,005 Cr.
Book Value per Share
₹115.9
P/E Ratio
53.90
Higher than its 5-year historical median
Industry PE
54.8
Price to Book (P/B)
5.95
Higher than its 5-year historical median
Price to Sales (P/S)
7.30
Higher than its 5-year historical median
EV/EBITDA
29.08
Higher than its 5-year historical median
Dividend Yield
0.21%
Profitability Efficiency
Return on Equity (ROE)
12.11%
Outperforms industry median
Return on Capital Employed (ROCE)
17.40%
Outperforms industry median
Return on Assets (ROA)
9.70%
Operating Profit Margin
16.5%
Net Profit Margin
14.53%
Gross Profit Margin
23.3%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
9.38%
Operating Profit Growth (1 Year)
Improving versus 3-year growth rate
17.8%
Net Profit Growth (1 Year)
Improving versus 3-year growth rate
49.27%
Asset Quality
Promoter Holding
35.01%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹1,222 Cr.
Equity
₹10.6 Cr.
Face Value
₹1
All Time Low / High
₹0.04 / 733.75
Check Before You Invest
Quality
Somewhat GoodValuation
OvervaluedCheck Valuation charts
Price Trend
Strong
Is Bliss GVS Pharma Ltd a good quality company?
Bliss GVS Pharma Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Bliss GVS Pharma Ltd performance compare with that of its Peers?
Revenue growth of Bliss GVS Pharma Ltd vs industry peers?
Bliss GVS Pharma Ltd revenue CAGR is 9.94%, compared to the industry median CAGR of 0%, indicating faster growth and gaining its market share.
Promoter shareholding and pledge status of Bliss GVS Pharma Ltd?
Promoters hold 35.01% of the Bliss GVS Pharma Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Bliss GVS Pharma Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 16.8% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Bliss GVS Pharma Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good
Value Creation ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 19.3% | 15.6% | 18.8% | 17.8% | 12% | 14.7% | 12.9% | 7.4% | 9.3% | 12.8% | - |
| Value Creation Index ⓘ | 0.4 | 0.1 | 0.3 | 0.3 | -0.1 | 0.1 | -0.1 | -0.5 | -0.3 | -0.1 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 348 | 298 | 427 | 442 | 466 | 636 | 598 | 605 | 667 | 730 | 788 |
| Sales YoY Gr. | - | -14.4% | 43.2% | 3.6% | 5.3% | 36.7% | -6% | 1.2% | 10.2% | 9.4% | - |
| Adj EPS ⓘ | 5.8 | 5.2 | 5.4 | 7 | 6 | 7.5 | 5.6 | 6.6 | 5.2 | 7.6 | 10.8 |
| YoY Gr. | - | -10.8% | 4.3% | 29.6% | -13.2% | 23.3% | -24.7% | 16.8% | -20% | 44.3% | - |
| BVPS (₹) ⓘ | 47.7 | 52.5 | 58.5 | 66.2 | 72.3 | 81.2 | 89.1 | 93.7 | 99.9 | 108.1 | 111.2 |
| Adj Net Profit ⓘ | 59.5 | 53.2 | 55.3 | 71.8 | 62.3 | 77.3 | 58.4 | 68.6 | 55.2 | 80 | 114 |
| Cash Flow from Ops. ⓘ | 38.5 | 22.7 | 48.3 | 63.2 | 67 | 114 | 43.8 | 82.2 | 97.2 | 123 | - |
| Debt/CF from Ops. ⓘ | 2 | 4.1 | 1.5 | 1.4 | 1.3 | 0.8 | 1.8 | 0.8 | 0.5 | 0 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 8.6% | 9.4% | 6.8% | 9.4% | ||||
| Adj EPS ⓘ | 3.1% | 4.6% | 10.5% | 44.3% | ||||
| BVPSⓘ | 9.5% | 8.4% | 6.7% | 8.2% | ||||
| Share Price | 17.1% | 44.6% | 97.2% | 365.8% | ||||
Key Financial Parameters ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 12.9 | 10.3 | 9.7 | 11.2 | 8.7 | 9.6 | 6.5 | 7.1 | 5.4 | 7.2 | 9.8 |
| Op. Profit Mgn % ⓘ | 29 | 29.7 | 22.4 | 22.7 | 19.7 | 17.2 | 15.1 | 17.7 | 13.8 | 16.3 | 17.9 |
| Net Profit Mgn % ⓘ | 17.1 | 17.9 | 13 | 16.2 | 13.4 | 12.1 | 9.8 | 11.3 | 8.3 | 11 | 14.5 |
| Debt to Equity ⓘ | 0.2 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0 | - |
| Working Cap Days ⓘ | 533 | 621 | 442 | 443 | 471 | 372 | 419 | 400 | 326 | 332 | 184 |
| Cash Conv. Cycle ⓘ | 206 | 270 | 269 | 307 | 293 | 212 | 233 | 242 | 223 | 208 | 146 |
Valuation of Bliss GVS Pharma - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 798 | 815 | 899 | 689 | 577 | 747 | 752 | 770 | 810 | 927 |
| Operating Expenses ⓘ + | 596 | 618 | 741 | 566 | 471 | 629 | 634 | 620 | 683 | 778 |
| Operating Profit ⓘ | 203 | 197 | 158 | 123 | 107 | 118 | 117 | 151 | 127 | 149 |
| Operating Profit Margin (%) | 25.4% | 24.2% | 17.5% | 17.9% | 18.5% | 15.8% | 15.6% | 19.6% | 15.6% | 16.1% |
| Other Income ⓘ + | 13 | 27 | 38 | 39 | 22 | 31 | 18 | 29 | 36 | 88 |
| Interest ⓘ | 20 | 23 | 4 | 8 | 7 | 5 | 10 | 7 | 8 | 12 |
| Depreciation ⓘ | 20 | 21 | 9 | 13 | 17 | 17 | 19 | 26 | 29 | 33 |
| Profit Before Tax ⓘ | 175 | 145 | 182 | 129 | 104 | 54 | 106 | 117 | 126 | 190 |
| Tax ⓘ | 63 | 57 | 55 | 34 | 30 | 31 | 29 | 35 | 35 | 55 |
| Profit After Tax | 113 | 89 | 127 | 95 | 74 | 23 | 77 | 82 | 90 | 135 |
| PAT Margin (%) | 14.1% | 10.9% | 14.1% | 13.8% | 12.8% | 3.1% | 10.2% | 10.6% | 11.2% | 14.5% |
| Adjusted EPS (₹) | 8.0 | 5.7 | 12.0 | 9.4 | 6.6 | 1.5 | 6.8 | 7.2 | 8.0 | 12.2 |
| Dividend Payout Ratio (%) | 7.50% | 17.60% | 8.30% | 5.30% | 7.50% | 34.50% | 7.40% | 6.90% | 6.30% | 12.30% |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 487 | 536 | 646 | 736 | 798 | 809 | 875 | 959 | 1,044 | 1,181 | |
| Debt + | 213 | 112 | 97 | 104 | 98 | 84 | 87 | 68 | 43 | 3 | |
| Minority Interest | 66 | 11 | 14 | 15 | 20 | 28 | 34 | 36 | 41 | 39 | |
| Trade Payables | 98 | 58 | 79 | 90 | 74 | 93 | 86 | 61 | 71 | 104 | |
| Others Liabilities ⓘ | 159 | 142 | 69 | 83 | 87 | 96 | 72 | 88 | 102 | 149 | |
| Total Liabilities ⓘ | 1,023 | 860 | 905 | 1,027 | 1,077 | 1,109 | 1,154 | 1,212 | 1,301 | 1,476 | |
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 304 | 136 | 145 | 241 | 234 | 281 | 378 | 369 | 405 | 459 | |
| CWIP ⓘ | 4 | 0 | 47 | 0 | 2 | 22 | 3 | 8 | 21 | 6 | |
| Investments ⓘ | 1 | 6 | 1 | 1 | 0 | 2 | 8 | 4 | 4 | 5 | |
| Inventories | 49 | 59 | 77 | 74 | 99 | 124 | 103 | 118 | 126 | 151 | |
| Trade Receivables | 254 | 298 | 461 | 548 | 464 | 393 | 385 | 404 | 439 | 517 | |
| Cash Equivalents | 150 | 89 | 107 | 103 | 145 | 178 | 103 | 216 | 213 | 167 | |
| Others Assets ⓘ | 260 | 270 | 68 | 60 | 133 | 109 | 174 | 92 | 93 | 172 | |
| Total Assets ⓘ | 1,023 | 860 | 905 | 1,027 | 1,077 | 1,109 | 1,154 | 1,212 | 1,301 | 1,476 | |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 289 | 18 | 40 | 47 | 64 | 135 | 34 | 103 | 106 | 139 |
| Cash Flow From Investing Activity ⓘ + | -231 | 50 | -74 | -48 | -47 | -93 | -8 | -83 | -76 | -38 |
| Cash Flow From Financing Activity ⓘ + | -10 | -76 | 17 | -6 | -21 | -24 | -25 | -21 | -30 | -89 |
| Net Cash Flow ⓘ | 48 | -8 | -17 | -7 | -4 | 19 | 2 | -1 | 0 | 11 |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 25.06 | 17.34 | 21.43 | 13.79 | 9.64 | 2.88 | 9.11 | 8.89 | 9.01 | 12.11 |
| ROCE (%) | 31.06 | 24.61 | 26.58 | 17.02 | 12.49 | 6.37 | 12.22 | 12.15 | 12.29 | 17.4 |
| Asset Turnover Ratio | 0.85 | 0.87 | 1.02 | 0.71 | 0.55 | 0.68 | 0.66 | 0.65 | 0.67 | 0.7 |
| PAT to CFO Conversion(x) | 2.56 | 0.2 | 0.31 | 0.49 | 0.86 | 5.87 | 0.44 | 1.26 | 1.18 | 1.03 |
| Working Capital Days | ||||||||||
| Receivable Days | 126.30 | 123.80 | 154.20 | 267.10 | 319.90 | 209.10 | 188.90 | 187.10 | 182.60 | 180.10 |
| Inventory Days | 20 | 24.30 | 27.70 | 40.10 | 54.70 | 54.40 | 55.10 | 52.50 | 52.90 | 52.10 |
| Payable Days | 105.10 | 73.10 | 40.90 | 70 | 90.90 | 77.90 | 81.40 | 70.40 | 58.40 | 75.40 |
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Bliss GVS Pharma Ltd FAQs
The current trading price of Bliss GVS Pharma on 23-Sep-2026 11:43 is ₹704.0.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 22-Sep-2026 the market cap of Bliss GVS Pharma stood at ₹7,341.1 Cr
The latest P/E ratio of Bliss GVS Pharma as of 22-Sep-2026 is 64.15.
The latest P/B ratio of Bliss GVS Pharma as of 22-Sep-2026 is 6.21.
The 52-week high of Bliss GVS Pharma is ₹733.8 and the 52-week low is ₹118.3.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Bliss GVS Pharma is ₹788 ( Cr.) .
Past 10 year's financial track record analysis by Moneyworks4me indicates that Bliss GVS Pharma Ltd is a average quality company.
The key valuation ratios of Bliss GVS Pharma Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Bliss GVS Pharma Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing
About Bliss GVS Pharma Ltd
Bliss Gvs Pharma Limited was incorporated on December 11, 1984, as Public Limited Company with a proven track record of developing, manufacturing and marketing high quality pharmaceutical formulations at affordable prices for the global market. The company has established a foothold in various therapeutic categories including anti-malarial, anti-fungal, contraceptive, laxative, anti-haemorrhoidal, anti-spasmodic, anti-biotic, anti-microbial, antiinflammatory, anti-pyretic, analgesic, and several others.
It is among the world leaders in Suppositories and Pessaries dosage forms with one of the largest portfolios in this segment. Over the last decade, it has acquired definitive know-how in other dosage forms & therapeutic segments, which is exemplified by its ever-expanding product offering across more than sixty countries. With significant expansion in R & D, Manufacturing & Marketing capabilities, the company is poised for an accelerated rate of growth which makes for very exciting times at Bliss GVS.
Business area of the company
It is a fast-growing Pharmaceutical Company with a proven track record of developing, manufacturing and marketing high quality pharmaceutical formulations at affordable prices for the global market. The company’s most unique product is ‘Today Vaginal Contraceptive’, a safe female contraceptive aimed at furthering Planned Parenthood and is also an established method for preventing conception. Bliss also manufactures to US specification vaginal pessaries of Clotrimazole & Povidone Iodine in addition to Anal Suppositories for treatment of piles. The company also manufacture wide range of Pessary Formulations, Suppository Formulations, Calcium Preparation, Protein Powders, Iron Preparation, Antibiotics, Analgesic & Antipyretics, Respiratory, Anti-inflammatory, Dermatological Preparations, Anti-Diarrhoeal products.
Key Milestones
- 1984: Incorporated as Bliss Chemicals and Pharmaceuticals Limited.
- 1986: Launch of Flagship product ‘TODAY’, a vaginal contraceptive.
- 2006: Merger of GVS Labs with Bliss Chemicals & Pharma to form Bliss GVS Pharma Ltd.
- 2007: Commissioning of manufacturing units for Tablets & Dry Syrups at Palghar.
- 2010: Commissioning of a state-of-the-artfacility for Suppositories and Pessaries.
- 2011: EU-GMP approval to the manufacturing facility for suppository facility.
- 2015: Setting up Healthcare Centres in East Africa under Bliss GVS Healthcare.
- 2017: Setting up offices in South East Asian countries.
- 2018: Divestment from Bliss GVS Healthcare.
- 2019: Setting up of multi-dosage facility (Vevoor Plant).
You have 48 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
